Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marylore Chenel

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Clinical Pharmacokinetics|December 6, 2012
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior informationCyrielle Dumont, France Mentré, Clare Gaynor, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial resultsMarylore Chenel, François Bouzom, Fanny Cazade, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2003
Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamateMarylore Chenel, Anne Limosin, Sandrine Marchand, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2017
Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modellingKathryn Ball, Tanguy Jamier, Yannick Parmentier, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministrationSandrine Marchand, Anna Forsell, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2021
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approachElena M Tosca, Glenn Gauderat, Sylvain Fouliard, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) ModelingSalih Benamara, Erik Sjögren, Florence Gattacceca, et al.
Clinical Pharmacokinetics|March 11, 2010
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamilNathalie Perdaems, Helene Blasco, Cedric Vinson, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in ratsMarylore Chenel, Agnès Barbot, Antoine Dupuis, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Clinical Pharmacokinetics|December 6, 2012
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior informationCyrielle Dumont, France Mentré, Clare Gaynor, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial resultsMarylore Chenel, François Bouzom, Fanny Cazade, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2003
Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamateMarylore Chenel, Anne Limosin, Sandrine Marchand, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2017
Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modellingKathryn Ball, Tanguy Jamier, Yannick Parmentier, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministrationSandrine Marchand, Anna Forsell, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2021
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approachElena M Tosca, Glenn Gauderat, Sylvain Fouliard, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) ModelingSalih Benamara, Erik Sjögren, Florence Gattacceca, et al.
Clinical Pharmacokinetics|March 11, 2010
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamilNathalie Perdaems, Helene Blasco, Cedric Vinson, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in ratsMarylore Chenel, Agnès Barbot, Antoine Dupuis, et al.
Pageof 6